Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Cancer

Volumn 123, Issue 4, 2017, Pages 609-616

  Koller, Paul B ^a   Kantarjian, Hagop M ^a   Nogueras Gonzalez, Graciela M ^a   Jabbour, Elias ^a   Verstovsek, Srdan ^a   Borthakur, Gautam ^a   Estrov, Zeev ^a   Wierda, William G ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Ravandi, Farhad ^a   O'Brien, Susan M ^b   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic myeloid leukemia (CML); second cancer; survivor; tyrosine kinase inhibitor

Indexed keywords

CREATININE; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; AGING; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; EVENT FREE SURVIVAL; FAILURE-FREE SURVIVAL RATE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL HISTORY; MELANOMA; NON MELANOMA SKIN CANCER; ONCOLOGICAL PARAMETERS; PROSTATE CANCER; SURVIVAL RATE; TRANSFORMATION-FREE SURVIVAL; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 85011649896     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30362     Document Type: Article

References (24)

1. Hochhaus A, O'Brien SG, Guilhot F, et al; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–1061.
2. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–1987.
3. Sasaki K, Kantarjian HM, Jain P, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122:238–248.
4. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–561.
5. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–3127.
6. Gunnarsson N, Hoglund M, Stenke L, et al. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia. 2016;30:1562–1567.
7. Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8 + T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107–2118.
8. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366–1377.
9. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473–2479.
10. Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001;44:3965–3977.
11. Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer. 2010;46:1781–1789.
12. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006;49:6819–6832.
13. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375–381.
14. Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–214.
15. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
16. National Cancer Institute. Cancer trends progress report 2014 update. http://progressreport.cancer.gov/end/mortality#field_most_recent_estimates. Accessed July 22, 2015.
17. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734–3745.
18. Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118:4353–4358.
19. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515–6520.
20. Gunnarsson N, Stenke L, Hoglund M, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169:683–688.
21. Adra N, Sayar H, Einhorn LH. Chemotherapy-related chronic myelogenous leukemia: a case series of patients with germ cell tumor. JAMA Oncol. 2016;2:391–392.
22. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29:17–26.
23. Borthakur G, Estey AE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep. 2007;9:373–377.
24. Borthakur G, Lin E, Jain N, et al. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009;115:3217–3221.